Comparison of Two drugs in Urogenital Symptoms of Menopause
Phase 3
- Conditions
- Health Condition 1: N952- Postmenopausal atrophic vaginitis
- Registration Number
- CTRI/2024/03/064620
- Lead Sponsor
- Principal Investigator
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
post menopausal female of less than 60 years with genitourinary syndrome
Exclusion Criteria
post menopausal female with Hypertension, Diabetes Mellites, heart disease, chronic liver and kidney disease , already on any hormone therapy for menopausal symptoms, history of thromboembolism, benign or malignant breast disease or with past history of breast carcinoma, family history of breast carcinoma, abnormal uterine bleeding or known genital premalignant or malignant lesion , Endometrial thickness more than 5 mm in transvaginal sonography , BMI more than 30, on any psychiatric treatment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement in urogenital symptoms after treatment on menopausal rating scaleTimepoint: AFTER 3 MONTHS TREATMNT
- Secondary Outcome Measures
Name Time Method Vaginal Health Index & Vaginal Maturation IndexTimepoint: After 3 months of starting the treatment